0115 837 0503 info@aureliabio.com

3-D Cell Biology

We have developed a 3-D micro-tissue system from electrospun material that can be used in conjunction with well plates for higher throughput screening. Additionally, we use Ultra Low Attachment (ULA) plates to generate and culture spheroids.

Phenotypic Screening

We specialise in physiologically relevant assays using cell-based formats in state of the art technologies. We have used a number of human primary cells in a number of assay formats.

WES: Western Assay System

The WesTM system from ProteinSimple is a fully automated device which runs the Simple Western size assay; a highly reproducible and sensitive alternative to standard Western blotting assays.

High Content Screening

High Content Screening (HCS) uses microscopic imaging to observe, measure and analyse multiple parameters within cells in a biological assay.

Label-Free Screening

Our scientists have in-depth experience of label-free technology applied to cell-based assays gained over the past 6 years using Corning Epic, PerkinElmer EnSpire and SRU Bioscience Bind instruments.


PROTAC (PROtein TArgeted Chimeric) is the ability to specifically degrade a protein using the endogenous machinery of the cell. We have developed assays for PROTAC using WES (ProteinSimple) and NanoLuc (Promega). 

Cell-Based Screening

Cell based assays are of key importance at a number of stages in the drug discovery process. Being able to examine the interaction between your target and compounds in a cellular context is of great advantage.

High Throughput Screening

With over 20 years of screening experience we are adept at designing screening assays and screening 100,000 to 1 million compounds in 384 well and 1536 well plates.

FLIPR Screening

We use FLIPR in a range of assay formats, readouts and target types.

Kinase Compound Profiling

Using Promega’s NanoBRET™ technology, we have employed intracellular kinase assays designed to study the interaction of compounds on kinase targets in intact living cells.

Cell Culture Services

Typical screens have required upwards of 1010 cells. We have developed methodologies to grow, sub-culture, harvest, cryopreserve and revive these quantities of cells from single batches, thus reducing screening variability, allowing cells to be used in an identical manner to other assay reagents, reviving and using what is required on a daily basis.

Flow Cytometry

Flow cytometry can simultaneously analyse multiple parameters such as relative size, internal complexity, relative fluorescence intensity, etc on the same cell within seconds. 

Protein-Protein Interactions

We have successfully used NanoBRET™ System (Promega) to detect protein- protein interactions in living cells.

Quantitative PCR

Using our Applied Biosystems™ QuantStudio™ 6 Flex Real-Time PCR system, we are able to investigate quantitative differences in mRNA expression in relation to pathways and targets identified as being of interest to clients. 

Biochemical Screening

We have carried out biochemical screening for a range of targets including but not limited to proteases, kinases, phosphodiesterase enzymes and protein:protein interactions.

Instrument and Reagent Validation

Acting as an intermediary between instrument manufacturers and reagent manufacturers and prospective clients, we can provide an expert lab-based environment for the validation of new technologies.

Hypoxia and Cancer

We have developed a physiologically relevant human cell-based assay to screen small molecules for their ability to inhibit adaptive responses to hypoxia.

Customised bioassay development, pharmacological profiling and compound screening

Aurelia Bioscience is a pre-clinical contract research organisation (CRO) specialising in bioassay development, pharmacological profiling and compound screening.

We work in early stages of the drug discovery pipeline including target identification and validation, hit identification, hit to lead as well as lead identification and optimisation. We have significant experience of different target classes and use cutting edge technologies to deliver client projects in a timely, efficient and cost-effective manner.

New Vlog: A Practical Guide to Building a Successful Bioassay

In this video, we have outlined some practical steps to help optimise your finished assay. This is the 2nd vlog of a 6 vlog series on ‘How to Develop Effective In Vitro Assays for Early Drug Discovery’. For more insights, download our free e-book. Subscribe to...

Vlog: Key principles of assay design for project success

Watch our vlog to understand some key principles of bioassay design that can help you construct the best assay for your needs: https://youtu.be/3HX1QYLjWFY. This is the 2nd vlog of a 6 vlog series on ‘How to Develop Effective In Vitro Assays for Early Drug Discovery’....

New Vlog: The Importance of Bioassays in Early Drug Discovery

Watch our latest video where we have discussed some key points that need to be kept in mind whilst developing bioassays for reliable compound progression: https://youtu.be/D1AzVhDjWOQ . This is the 1st vlog of a 6 vlog series on 'How to Develop Effective In Vitro...

Job Vacancy: Senior Assay Development Scientist: Drug Discovery

Location: Nottingham NG1 1GF Salary: Highly competitive Type: Permanent, full time Are you experienced in developing biological assays within a contract research or similar client-facing drug discovery environment? Are you looking for a new opportunity to develop your...

Digital Book: A Guide to Drug Discovery

Dr. Gary Allenby, CEO, Aurelia Bioscience, elucidates the Hit Identification process with the help of examples and case studies in a digital guide published by Medicines Discovery Catapult://bit.ly/3bhzq1G. Contact us to learn more about our capabilities and services.

Webinar: Advancing Targeted Protein Degradation Research with Automated Western Blotting

Our CEO, Dr. Gary Allenby, talked on Advancing Targeted Protein Degradation Research with Automated Western Blotting WESS and JESS) at a webinar organised by Bio-Techne earlier this month. If you missed it, but would like to access it, follow the link.  

Our PhD and pharma trained scientists have decades of experience in pre-clinical discovery, designing and developing low, medium and high throughput assays for hits-to-lead, lead identification and lead optimisation drug discovery phases

Are you looking for a CRO to help you discover your next breakthrough drug?